Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-27 00:00:00 ET · period of report 2024-02-23 · accession 0000875320-24-000105 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-27 | 2024-02-23 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $431.79 | -9,386 | 136.5K | -6% | -$4.05M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-23 | F | D | 9,386 | $431.79 | 136,507 | D | — | — |